Key result
Inhibition of 20-HETE biosynthesis or blockade of its actions abolished remodeling of renal resistance arteries in experimental models of hypertension, independent of blood pressure elevation.
Why the study?
Does 20-HETE inhibition prevent microvascular remodeling in experimental models of hypertension?
Does 20-HETE inhibition prevent microvascular remodeling in experimental models of hypertension?
20-HETE is a key regulator of microvascular remodeling in hypertension, acting independently of blood pressure elevation and androgen levels.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for 20-HETE inhibition in hypertension; leaves open translation to human microvascular remodeling.
20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P-450 (Cyp)-derived arachidonic acid metabolite that has been shown to increase smooth muscle contractions and proliferation, stimulate endothelial dysfunction and activation, and promote hypertension. We examined if 20-HETE contributes to microvascular remodeling in hypertension. In Sprague-Dawley rats, administration of the 20-HETE biosynthesis inhibitor HET0016 or the 20-HETE antagonist N-20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-HEDE) prevented 5α-dihydrotestosterone (DHT)-induced increases in blood pressure as well as abrogated DHT-induced increases in the media-to-lumen ratio (M/L), media thickness, and collagen IV deposition in renal interlobar arteries. Reserpine prevented blood pressure elevation in DHT-treated rats but did not affect microvascular remodeling (M/L, media thickness, and collagen deposition); under these conditions, treatment with the 20-HETE antagonist attenuated microvascular remodeling, suggesting that 20-HETE contributes to DHT-induced vascular remodeling independent of blood pressure elevation. In Cyp4a14(-/-) mice, which display androgen-driven and 20-HETE-dependent hypertension, treatment with the 20-HETE antagonist abolished remodeling of renal resistance arteries measured as media thickness (24 ± 1 vs. 15 ± 1 μm) and M/L (0.29 ± 0.03 vs. 0.17 ± 0.01). Moreover, in Cyp4a12 transgenic mice in which the expression of Cyp4a12-20-HETE synthase is driven by a tetracycline-sensitive promoter, treatment with doxycycline resulted in blood pressure elevation (140 ± 4 vs. 92 ± 5 mmHg) and a significant increase in remodeling of renal resistance arteries (media thickness: 23 ± 1 vs. 16 ± 1 μm; M/L: 0.39 ± 0.04 vs. 0.23 ± 0.02); these increases were abrogated by cotreatment with 20-HEDE. This study demonstrated that 20-HETE is a key regulator of microvascular remodeling in hypertension; its effect is independent of blood pressure elevation and androgen levels.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2013) studied Hypertension and vascular remodeling. 20-HETE antagonist (20-HEDE or 20-HEDGE) or biosynthesis inhibitor (HET0016) vs. Vehicle or placebo was evaluated on Media thickness of renal resistance arteries in Cyp4a14-/- mice (μm) (p=<0.05). Inhibition of 20-HETE biosynthesis or blockade of its actions abolished remodeling of renal resistance arteries in experimental models of hypertension, independent of blood pressure elevation.
Synapse has enriched 10 related papers. Consider them for comparative context: